This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Cell Medica Limited. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Douglas Phillips: Innovator in Anti-PD-L1 Binding Members
Introduction
Douglas Phillips is a notable inventor based in Schlieren, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of binding members that target PD-L1. His work is crucial in the fight against cancer and inflammatory diseases.
Latest Patents
Phillips holds a patent for "Binding members to PD-L1." This invention focuses on anti-PD-L1 binding members, specifically monovalent, high potency PD-L1-binding antibody fragments that are highly stable and soluble. These binding members have potential applications in cancer treatment, inflammatory diseases, and diagnostics. The patent also includes related nucleic acids, vectors, cells, and compositions.
Career Highlights
Throughout his career, Douglas Phillips has worked with various companies, including Cell Medica Limited and Cell Medica Switzerland AG. His experience in these organizations has allowed him to advance his research and contribute to innovative solutions in the medical field.
Collaborations
Phillips has collaborated with notable individuals such as Abdijapar Shamshiev and Titus Kretzschmar. These partnerships have enhanced his research efforts and expanded the impact of his inventions.
Conclusion
Douglas Phillips is a prominent figure in the field of biotechnology, with a focus on anti-PD-L1 binding members. His innovative work has the potential to significantly impact cancer treatment and diagnostics.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile